Federated Hermes Inc. Sells 40,000 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Federated Hermes Inc. cut its holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) by 25.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,000 shares of the company’s stock after selling 40,000 shares during the period. Federated Hermes Inc.’s holdings in SOPHiA GENETICS were worth $565,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of SOPHiA GENETICS by 90.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock worth $65,000 after buying an additional 6,552 shares in the last quarter. Legato Capital Management LLC purchased a new stake in SOPHiA GENETICS in the 4th quarter worth $235,000. Finally, Banque Pictet & Cie SA boosted its holdings in shares of SOPHiA GENETICS by 2.3% during the 3rd quarter. Banque Pictet & Cie SA now owns 2,237,340 shares of the company’s stock valued at $5,705,000 after purchasing an additional 50,000 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SOPH. BTIG Research boosted their target price on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Wednesday, March 6th.

SOPHiA GENETICS Stock Down 1.6 %

Shares of NASDAQ:SOPH opened at $5.00 on Friday. The firm has a fifty day simple moving average of $4.92 and a two-hundred day simple moving average of $4.51. SOPHiA GENETICS SA has a 52 week low of $2.13 and a 52 week high of $7.37. The stock has a market capitalization of $326.15 million, a P/E ratio of -4.16 and a beta of 1.12.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.12). The company had revenue of $17.05 million during the quarter, compared to analysts’ expectations of $16.78 million. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the prior year, the business posted ($0.22) EPS. On average, analysts expect that SOPHiA GENETICS SA will post -1.02 earnings per share for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.